Answers are grounded in this paper and cite their sources.
Type 1 diabetes mellitus (T1DM) is a prevalent endocrine disorder characterized by autoimmune-mediated pancreatic β-cell dysfunction and chronic hyperglycemia. This study aimed to evaluate the diagnostic efficiency of biochemical markers, autoimmune antibodies, and circulating microRNA-375 in patients with T1DM compared to healthy controls. We recruited 100 patients with T1DM and 50 age-matched healthy controls (aged 1–25 years) from a specialized endocrinology and diabetes center in Baghdad between January and March 2025. We extracted total RNA from whole-blood samples and quantified relative miRNA-375 expression using stem-loop reverse transcription-quantitative PCR (RT-qPCR). We systematically evaluated clinicopathological characteristics and biochemical profiles. Patients with T1DM showed significant upregulation of miRNA-375, with a 3.94-fold increase compared with the healthy control group (p <0.05). Serum levels of the autoantibodies anti-ZnT8 and anti-IA-2 were also significantly elevated in the T1DM group. Furthermore, we found a significant positive correlation between miRNA-375 expression and HbA1c concentrations (r=0.201, p =0.045), suggesting a clinical link between microRNA dysregulation and glycemic control. In conclusion, these findings show that miRNA-375 is significantly upregulated in patients with T1DM, highlighting its potential as a minimally invasive molecular biomarker for early diagnosis and clinical monitoring.
No takes yet. Share an insight, caveat, or question.
Alzubaidi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: